Subcellular compartmentalization of PDEs (phosphodiesterases) is a major mechanism for the regulation of cAMP signalling. The identification of the proteins that recruit specific PDE isoforms to subcellular compartments can shed light on the regulation of spatial and temporal cAMP gradients in living cells and provide novel therapeutic targets for inhibiting functions of PDEs. We showed recently that p75 NTR (p75 neurotrophin receptor) interacts directly with a single PDE isoform, namely PDE4A4/5, via binding to its unique C-terminal region, and targets cAMP degradation to the membrane. The purpose of this review is to present the biological significance of PDE4A compartmentalization by p75 NTR and discuss the potential of inhibiting the interaction between p75 NTR and PDE4A for the development of an isoform-specific inhihibitor for PDEs.
Introduction
cAMP is a ubiquitous second messenger involved in regulating several signalling pathways in the CNS (central nervous system) [1] . cAMP has been implicated in numerous physiological nervous system processes such as synaptic transmission [2] , chemosensation [3] and long-term potentiation [4] . Regulation of cAMP signalling is vital for the maintenance of several functions within the CNS. Indeed, down-regulation of cAMP signalling underlies a variety of CNS disorders, including depression and addiction, and plays a major role in synaptic activity and axonal regeneration after injury (reviewed in [5] [6] [7] [8] ). One of the primary means of regulation of cAMP levels within the CNS occurs at the level of cAMP degradation, a process catalysed by PDEs (phosphodiesterases). There are 11 different families of PDEs, with 21 different genes encoding more than 50 different PDE isoforms (reviewed in [6, 9] ). The various PDE isoforms differ in their cellular distribution, means of regulation and subcellular compartmentalization. Because of the importance of PDEs in regulating cAMP levels in the CNS, PDEs have long been recognized as a therapeutic target [6, 9] . Elevation of cAMP by rolipram, a specific inhibitor for all PDE4 isoforms, has antidepressant effects [7] , increases axonal regeneration after spinal cord injury [8] , reduces neuroinflammation in an animal model of MS (multiple sclerosis) [10] and improves synaptic and cognitive function in an animal model of AD (Alzheimer's disease) [11] . However the lack of selectivity among PDE4 inhibitors leads to significant side effects and, coupled to the relative lack of understanding of the specific biological functions of each PDE4 isoform, has greatly limited the clinical applications of PDE4 inhibitors as drugs.
The neurotrophin receptor p75
NTR interacts directly with PDE4A to target cAMP degradation to the plasma membrane
The p75
NTR is classified as a member of the TNFR (tumour necrosis factor receptor) superfamily. p75 NTR is expressed after injury in several tissues by a wide range of cell types, such as smooth muscle cells, endothelial cells, myofibroblasts, neurons and glia, and has been shown to modulate disease progression by regulating several functions vital for tissue repair, including apoptosis [12] , cellular differentiation [13] , extracellular matrix remodelling [14] , myelination [15] and inhibition of neurite outgrowth [16, 17] . p75 NTR regulates such a divergent set of functions by activating distinct signalling pathways, such as RhoA [15, 16] , phosphoinositide 3-kinase and JNK (c-Jun N-terminal kinase) [18] , via differential interactions with extracellular ligands, co-receptors and intracellular signalling molecules (reviewed in [19] ). Depending on the nature of the injury, cell types and signalling pathways involved, p75
NTR can have diverse and often opposing biological functions [20] and can either promote or inhibit the overall process of tissue repair.
We recently identified regulation of cAMP as a novel molecular mechanism downstream of p75 NTR [14] . We showed that p75 NTR interacts directly with PDE4A to degrade cAMP [14] . Endogenous co-immunoprecipitation experiments in primary murine CGNs (cerebellar granule neurons) showed a specific interaction between p75 NTR and the PDE4A5 isoform ( Figure 1A ). Interestingly, using isoform-specific antibodies, we did not observe any interaction with the other PDE4 isoforms, namely PDE4B, PDE4C and PDE4D. In vitro binding assays confirmed the direct interaction as recombinant p75
NTR co-immunoprecipitated with recombinant PDE4A, but not PDE4D [14] . The interaction of p75 NTR with PDE4A as recombinant proteins in a cell-free system indicated the direct nature of this interaction. Cells expressing p75 NTR showed a reduction in intracellular cAMP [14] . Down-regulation of cAMP by p75 NTR was rescued by the PDE4 inhibitor rolipram, which is in accordance with the interaction of p75 NTR with the PDE4A isoform. Moreover, FRET (fluorescence resonance energy transfer) using a genetically encoded protein A-kinase activity reporter, AKAR3, showed reduction of PKA (protein kinase A) activation upon expression of p75 NTR (Figures 2A and 2B ). These results suggest that p75 NTR down-regulates cAMP/PKA signalling. Since p75
NTR is known to recruit intracellular mediators to the plasma membrane, we examined whether it was possible that p75 NTR recruited PDE4A to the membrane. Recruitment of PDE4 to subcellular structures such as the plasma membrane concentrates the activity of PDEs and reduces PKA activity by enhancing local degradation of cAMP [21] . To examine whether the p75 NTR -PDE4A interaction would result in decreased membrane-associated cAMP/PKA signalling, we performed FRET using a plasma membrane-targeted genetically encoded protein A-kinase activity reporter, pm-AKAR3, that generates a change in FRET when PKA is activated at the membrane of living cells.
Cells expressing p75
NTR showed an attenuated response as a change in emission ratio for the pm-AKAR3 in response to forskolin, suggesting reduced PKA activity at the membrane ( Figures 2C and 2D ). These results suggest that the association of PDE4A with p75 NTR targets cAMP degradation to the membrane, resulting in reduced PKA activity.
The unique C-terminus of PDE4A5 interacts directly with p75 NTR
PDE4s have been shown previously to interact with transmembrane receptors and, in particular, with β 2 -adrenergic receptors [22] . By contrast with p75 NTR , which interacts only with the PDE4A isoform, β 2 -adrenergic receptors interact with all PDE4 isoforms via an adaptor protein, β-arrestin [22] . The capacity of β-adrenergic receptors to interact non-selectively with all PDE4 isoforms is due to the binding of β-arrestin to the N-terminal region that is highly homologous among all PDE4s. We therefore reasoned that the selectivity of the interaction between p75 NTR and PDE4A might be due to an interacting domain that would be unique to PDE4A. Indeed, PDE4A is known as the long PDE4 isoform. We therefore examined whether p75 NTR interacted with the unique C-terminal region of PDE4A. Deletion of the C-terminal region of PDE4A abolished its interaction with p75 NTR ( Figure 1B) . Moreover, screening of a PDE4A peptide array demonstrated specific and direct interaction of p75 NTR primarily with sequences within the extreme C-terminal region of PDE4A4 that are not present in other PDE4s (peptides 172 and 173, amino acids 856-885, sequence KRACSACAGTFGEDTSAL-PAPGGGGSGGDP) ( Figure 1C) . Interestingly, the p75 NTRinteracting sequences within the C-terminal domain are highly conserved between the human PDE4A4 and the rodent PDE4A5. Indeed, peptide array screening for PDE4A5 revealed direct interaction with p75 NTR , similar to PDE4A4. What is the biological function of the decrease in cAMP via the interaction of p75 NTR with PDE4A4? One mechanism whereby cAMP can mediate its CNS effects is via the regulation of expression of specific genes, including arginase I [23] , interleukin 6 [24] and tPA (tissue plasminogen activator) [25] . Expression of p75 NTR at sites of injury both within and outside of the nervous system correlates with vascular rupture and deposition of fibrin. Up-regulation of p75 NTR is frequently observed in MS [26, 27] , AD [28] , stroke [29] , spinal cord [30] and sciatic nerve injury [31] , all of which are associated with fibrin deposition. Interestingly, studies from our laboratory have shown that fibrin deposition in the nervous system is not merely a marker but a mediator of disease pathogenesis, since depletion of fibrin either genetically or pharmacologically results in dramatic improvement in peripheral nerve regeneration [32] and suppression of inflammatory demyelination and paralysis in animal models of MS [33, 34] . In addition, fibrin regulates inflammation and vascular pathology in animal models of AD [35] and brain ischaemia/hypoxia [36] . p75 NTR is also up-regulated in non-nervous system diseases associated with defects in fibrin degradation, such as atherosclerosis [37] , pancreatitis [38] , melanoma formation [39] , lung inflammation [40] , cancer [41] and liver disease [42] . Fibrin degradation is a critical step in tissue repair, since genetically engineered mice with a deficiency in plasmin, the serine protease that degrades fibrin, show wasting, premature death, necrosis in multiple tissues and delayed wound healing. It is noteworthy that genetic depletion of fibrinogen rescues the effects of plasminogen deficiency in both peripheral [43] and neural [44] tissues, demonstrating further the contribution of proteolytic degradation of fibrinogen to tissue repair.
Our work showed that a biological function of the expression of p75 NTR at sites of injury is inhibition of fibrin degradation via suppression of the tPA/plasmin proteolytic system. We showed that p75 NTR−/− mice show increased tPA activity and fibrin degradation after sciatic nerve injury or in the lung in a model of LPS (lipopolysaccharide)-induced fibrosis [14] . Although tPA participates in a plethora of nervous system functions, the mechanisms that regulate tPA remain poorly understood. tPA has been identified as an immediate-early gene which is regulated by cAMP [25] and is transcriptionally induced by brain activity [45] . Our studies showed that p75 NTR−/− mice had increased levels of cAMP after nerve injury and increased levels of tPA activity and mRNA [14] . Elevation of cAMP by in vivo administration of the PDE4 inhibitor rolipram also increased fibrin clearance after sciatic nerve injury and after LPS-induced lung fibrosis [14] . Overall, these results suggested that p75 NTR -mediated perpetuates scar formation and suppresses extracellular matrix remodelling. Rolipram inhibits all PDE4s, including PDE4A, by acting on the highly conserved catalytic domain. By contrast, p75 NTR interacts with the unique C-terminal region of PDE4A, suggesting that inhibition of the interaction of p75 NTR with PDE4A could potentially lead to an isoform-specific inhibitor for PDE4A. ECM, extracellular matrix.
down-regulation of cAMP decreases tPA, resulting in the perpetuation of fibrin deposits at sites of injury.
Discussion
Our recent studies showed regulation of cAMP as a novel molecular pathway downstream of p75 NTR ( Figure 3 ). We showed that p75 NTR -mediated suppression of cAMP signalling regulates extracellular matrix remodelling in sciatic nerves and lungs [14] . It is noteworthy that inhibitory functions of p75 NTR in axonal regeneration [17, 46] are disinhibited by elevation of cAMP in neurons, either via the addition of cAMP analogues or via priming with neurotrophins [47] . In addition, rolipram has also been shown to overcome inhibition of neurite outgrowth and promote functional recovery in the spinal cord after injury [48] . In addition to the nervous system, PDE4 is considered a major pharmacological target for lung pathogenesis, especially for COPD (chronic obstructive pulmonary disease) [6] , and PDE4A4 is the PDE4 isoform that is specifically up-regulated in lung disease [49] . Our results support a biological role for the interaction between p75 NTR and PDE4A in the regulation of cAMP in both the nervous system and lungs [14] .
Pharmacological targeting of PDEs has so far focused on generating inhibitors of the catalytic domain (Figure 3 ). Since the catalytic domain is highly homologous between the different isoforms, the present PDE4 inhibitors are nonselective and are thus associated with various side effects that limit their clinical applications. By contrast, the identification that regulation of cAMP is mediated by direct binding of p75 NTR to the unique C-terminal region of PDE4A4/5 [14] potentially reveals a more specific target for therapeutic intervention ( Figure 3) . The unique C-terminal region of PDE4A4/5 is not shared by other PDE4 isoforms and thus provides the potential for the generation of an isoformspecific inhibitor for PDE4A. Rolipram, a general inhibitor of PDE4s, has deleterious side effects due to inhibition of PDE4D, including nausea, when given to patients and thus has a limited therapeutic value. Specific inhibitors of PDE4s that would decrease unwanted side effects could potentially have great therapeutic value in both diseases of the lung and the nervous system. Interestingly, PDE4A appears to be a PDE4 isoform up-regulated in COPD [49] and the corticospinal tract [50] . Our recent studies suggest that it might be possible to specifically inhibit the activation of the PDE4A isoform by perturbing its subcellular compartmentalization via inhibition of the binding of p75 NTR to the unique C-terminal region of PDE4A. Likewise, by specifically blocking the interaction between p75 NTR and PDE4A4/5, other signalling through p75 NTR would be preserved. A greater understanding of the biological functions of PDE4A and the cell types and disease processes in which p75 NTR and PDE4A4/5 are co-expressed will probably lead to additional targets for p75 NTR -PDE4A4/5-based therapies.
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